LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
Achieved total revenue of RMB 371.9 million,reflecting a growth of 36.2% YoY Achieved gross profit ofRMB 307.3 million,a growth of 39.1% YoY